ovarian clear cell adenocarcinoma (Cancer)
Information
- Disease name
- ovarian clear cell adenocarcinoma
- Disease ID
- DOID:5304
- Description
- "A ovarian adenocarcinoma that derives_from epithelial cells which have clear cytoplasm." [url:https\://www.ncbi.nlm.nih.gov/pubmed/25398420]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02502266 | Active, not recruiting | Phase 2/Phase 3 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | May 3, 2016 | June 30, 2024 |
| NCT00565851 | Active, not recruiting | Phase 3 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | December 6, 2007 | January 1, 2028 |
| NCT02020707 | Active, not recruiting | Phase 1 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | February 24, 2014 | June 30, 2025 |
| NCT02068794 | Active, not recruiting | Phase 1/Phase 2 | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | March 31, 2014 | December 31, 2024 |
| NCT02364713 | Active, not recruiting | Phase 2 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | March 13, 2015 | February 28, 2028 |
| NCT02446600 | Active, not recruiting | Phase 3 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 28, 2016 | August 9, 2024 |
| NCT00979992 | Completed | Phase 2 | Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer | April 19, 2010 | February 9, 2019 |
| NCT00989651 | Completed | Phase 1 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | October 28, 2009 | April 10, 2020 |
| NCT01074411 | Completed | Phase 1 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | April 5, 2010 | January 27, 2018 |
| NCT01097746 | Completed | Phase 2 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | April 14, 2010 | September 13, 2022 |
| NCT01504126 | Completed | Early Phase 1 | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | March 9, 2012 | August 15, 2019 |
| NCT00262847 | Completed | Phase 3 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | September 2005 | April 2015 |
| NCT02315430 | Completed | Phase 2 | Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | April 1, 2015 | February 9, 2019 |
| NCT02853318 | Completed | Phase 2 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | September 1, 2016 | June 30, 2021 |
| NCT00888615 | Completed | Phase 2 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | December 13, 2010 | August 31, 2016 |
| NCT00951496 | Completed | Phase 3 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | August 11, 2009 | January 11, 2016 |
| NCT05950464 | Recruiting | Phase 1 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | December 18, 2023 | April 30, 2026 |
| NCT04575935 | Recruiting | Phase 3 | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | August 5, 2020 | December 31, 2028 |
| NCT04919629 | Recruiting | Phase 2 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | February 17, 2023 | December 1, 2025 |
| NCT05226507 | Recruiting | Phase 1 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | December 31, 2021 | June 2025 |
| NCT05231122 | Recruiting | Phase 2 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | March 12, 2024 | December 30, 2026 |
| NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
| NCT02923739 | Terminated | Phase 2 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | May 5, 2017 | September 27, 2022 |
| NCT03641287 | Terminated | N/A | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors | December 5, 2018 | September 30, 2022 |
| NCT03924245 | Terminated | Phase 1 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | October 1, 2020 | February 4, 2022 |
| NCT03648489 | Unknown status | Phase 2 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | September 21, 2018 | December 2022 |
| NCT00719303 | Unknown status | Phase 3 | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | June 18, 2012 | |
| NCT00108745 | Unknown status | Phase 3 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | March 21, 2005 | February 22, 2022 |
| NCT02713386 | Unknown status | Phase 1/Phase 2 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | November 14, 2016 | September 30, 2022 |
- Disase is a (Disease Ontology)
- DOID:3713
- Cross Reference ID (Disease Ontology)
- NCI:C40078
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:763131005
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1518693